StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Prashant P. Sawant

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byPrashant P. SawantHorizon: NA (inferred Intraday)29 Jul 2026, 10:06 am ISTvia CNBC Awaaz.

Entry₹2,210Inferred
Target₹2,250
Total upside +1.81% (call closed)
Stop loss₹2,195-0.68% risk
Exit₹2,19529 Jul 2026, 10:28 am
Stop-loss hit-0.68%
Follow Prashant P. Sawant for new calls(5% target hit, 19 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 29 Jul 2026
2 supporting0 opposing
Supports the BUY call (2)

Glenmark Pharmaceuticals Inc., USA has launched Sugammadex Injection in single-dose vials, available in 200 mg/2mL and 500 mg/5mL strengths.

BSE · Company Update·28 Jul · today

(opens in new tab)

1 advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·24 Jul · 4d ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Prashant P. Sawant

Every call and its outcome